Overcoming Scalability Challenges with Autologous Therapies
Summary: Autologous immunotherapies have evolved in recent years to bring breakthrough treatments to the market. However, the complexity of the production process often results in extended timelines and high manufacturing costs, limiting the scalability and application across therapeutic indications. Therefore, cell therapy providers continue to make new investments to develop standardized and optimized scale-out strategies while balancing the customized processes for each patient treatment.
In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies. Professor Gerhard Bauer discusses the current challenges associated with autologous therapies and Dr. James Crutchley speaks to the various solutions available for commercial scale-up of advanced therapeutics.